312 related articles for article (PubMed ID: 31466582)
1. Systemic Therapies for Advanced Melanoma.
Bomar L; Senithilnathan A; Ahn C
Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
[TBL] [Abstract][Full Text] [Related]
2. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
3. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
5. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
6. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
7. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
8. Management of Metastatic Melanoma in 2018.
Kaufman HL; Margolin K; Sullivan R
JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
[No Abstract] [Full Text] [Related]
9. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
10. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
11. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
[TBL] [Abstract][Full Text] [Related]
12. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
14. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
15. [Systemic treatment of melanoma brain metastases].
Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
[TBL] [Abstract][Full Text] [Related]
16. [Great advances in the systemic treatment in malignant melanoma patients].
Ullenhag G; Hansson J; Ny L
Lakartidningen; 2017 May; 114():. PubMed ID: 28485771
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
18. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
20. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
